The board of directors of Nasdaq-listed company Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset
According to PR Newswire, Anixa Biosciences, Inc. (NASDAQ: ANIX), a Nasdaq-listed company in the United States, announced that its board of directors has approved the purchase of Bitcoin as a treasury reserve asset with the aim of diversifying the company's assets and enabling Anixa to benefit from the potential long-term value of digital assets. It is reported that Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: A certain whale purchased 2,024 ETH and currently holds 7,066 ETH.
A certain whale has accumulated 7,066 ETH on HyperLiquid, with holdings exceeding $21.22 million.
Barcelona Football Club criticized for signing a $22 million sponsorship deal with crypto company ZKP
Swedish payment giant Klarna's first stablecoin, KlarnaUSD, has been launched ahead of schedule